Trial Profile
A retrospective study assessing efficacy and safety of sunitinib dosing regimens in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2015
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 12 Dec 2015 New trial record
- 01 Feb 2014 Primary endpoint (overall survival with continuous dosing (CD) regimen) has not been met.